While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2–4.9; p =.02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5–1.1; p =.099). AlloHCT in CP2 + [HR = 2.0 (0.8–4.9), p =.13] and AP [HR = 1.1 (0.6–2.1); p =.80] is less clear and should be determined on a case-by-case basis.
All Science Journal Classification (ASJC) codes
- Cancer Research